Thymosin Beta-4 Sulfoxide: Why Methionine Oxidation Is Not a TB-500 Fragment Result
Thymosin beta-4 sulfoxide is an oxidized form of the full-length 43-residue thymosin beta-4 protein, created when its methionine residue is converted to methionine sulfoxide. That chemistry cannot occur in the seven-residue TB-500 fragment Ac-LKKTETQ because the fragment contains no methionine. Results for thymosin beta-4 sulfoxide therefore must not be assigned to TB-500.
This is a precise identity boundary, not a minor naming preference. The TB-500 product record identifies the catalog material as the N-acetylated 17–23 fragment. The guide to TB-500 versus thymosin beta-4 explains the larger sequence distinction; this article focuses on oxidation.
Where the oxidizable residue occurs
The reviewed UniProt thymosin beta-4 entry records the full human thymosin beta-4 sequence. Methionine occurs near the N-terminus of that full-length sequence. Oxidation adds oxygen to the sulfur-containing side chain and changes chemical behavior without changing peptide length.
The short TB-500 fragment corresponds to a different region of thymosin beta-4. Its sequence, Ac-LKKTETQ, contains leucine, lysine, threonine, glutamate, and glutamine residues but no methionine. A report that labels this fragment “TB-500 sulfoxide” would therefore need extraordinary clarification because the named oxidation site is absent from the stated sequence.
What the original experiments measured
A primary study indexed by NIH PubMed reported that oxidation of thymosin beta-4 greatly reduced its actin polymerization-inhibiting capacity. That experiment concerned the full-length protein and an actin-related endpoint. It did not test Ac-LKKTETQ.
A later NIH PubMed study of thymosin beta-4 sulfoxide investigated anti-inflammatory activity generated in a defined monocyte and glucocorticoid context. The result illustrates another important boundary: oxidation may weaken one measured interaction while creating or changing activity in another model. “Oxidized” is not a universal synonym for inactive.
Older fragment work, including a DNase I inhibition assay comparison, examined actin-sequestering ability across thymosin beta-4, fragments, and related peptides. The material identity and assay endpoint must travel with every conclusion.
Full-length and fragment records answer different questions
| Record | Sequence feature | Oxidation question | Suitable evidence |
|---|---|---|---|
| Full-length thymosin beta-4 | 43 residues including methionine | Is methionine oxidized to sulfoxide? | Site-resolved MS, reference comparison |
| Thymosin beta-4 sulfoxide | Same length with oxidized methionine | How does oxidation change a defined assay? | Identity confirmation plus matched functional experiment |
| TB-500 fragment | Ac-LKKTETQ, seven residues | No methionine-sulfoxide site exists in the stated sequence | Intact mass, sequence confirmation, terminal-group check |
| Mixture or degraded sample | Potential multiple species | Which molecular species are present? | Chromatographic separation plus MS/MS |
The cell wound-closure evidence guide demonstrates why a result for full-length thymosin beta-4 cannot establish an effect for the fragment. The oxidation case is even more direct because the relevant residue is missing.
How to audit an oxidation claim
First, write the exact sequence and terminal groups. Second, mark every residue that can undergo the proposed modification. Third, calculate the expected mass change and decide whether the instrument can distinguish it. Fourth, require fragmentation or another site-resolved method when more than one location is possible. Finally, keep identity evidence separate from a functional assay.
For a material in the Recovery Peptides collection, the available COA should be read only for the lot and tests it actually describes. A purity chromatogram does not automatically identify an oxidation site, and a mass result does not establish actin binding or inflammatory signaling. The related BPC-157 + TB-500 Blend creates an additional mixture-level separation problem.
Research limitations
The cited papers concern defined full-length thymosin beta-4 species, fragments, and specific assay systems. They do not verify the current TB-500 product lot and do not support human or veterinary use. Oxidation during handling, deliberate preparation of a sulfoxide standard, and biological generation of an oxidized species are different experimental situations.
Frequently asked questions
Can TB-500 Ac-LKKTETQ form methionine sulfoxide?
No methionine is present in the stated seven-residue sequence, so that named modification cannot occur at a methionine site in this fragment.
Does oxidation always destroy thymosin beta-4 activity?
No. It can reduce a particular interaction while a different model measures another property. The material, method, and endpoint determine the conclusion.
Can a +16 Da mass shift prove methionine oxidation?
A +16 Da shift is consistent with oxidation but is not site-specific by itself. Sequence-resolved evidence is needed when alternative oxidation sites or species are possible.
Is full-length thymosin beta-4 sold as TB-500?
Names are used inconsistently across sources. The sequence and terminal groups, not the shorthand name, should determine the record.